Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy

Cell Cycle

Volumn 13, Issue 4, 2014, Pages 612-621

  Meregalli, Cristina ^a   Chiorazzi, Alessia ^a   Carozzi, Valentina A ^a   Canta, Annalisa ^a   Sala, Barbara ^a   Colombo, Matteo ^a   Oggioni, Norberto ^a   Ceresa, Cecilia ^a   Foudah, Dana ^a   La Russa, Federica ^b   Miloso, Mariarosaria ^a   Nicolini, Gabriella ^a   Marmiroli, Paola ^a   Bennett, David L H ^c   Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bortezomib; Neuronal cultures; Peripheral neuropathy; Proteasome inhibitor; tubulin polymerization

Indexed keywords

ALPHA TUBULIN; BORTEZOMIB; PROTEASOME; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TUBULIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; EMBRYO; ENZYME INHIBITION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; NERVE CELL CULTURE; NERVE CONDUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; RAT; REPEATED DRUG DOSE; SCIATIC NERVE; SENSORY NERVE CELL; SPINAL GANGLION; TREATMENT OUTCOME; ANIMAL; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; CELL LINE; GANGLIA, SPINAL; NEURONS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; RATS, WISTAR; SCIATIC NERVE; TUBULIN;

EID: 84896829819     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27476     Document Type: Article

References (46)

1. Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012; 51:823-9; PMID:23018466; http://dx.doi.org/10.1007/s40262- 012-0010-0
2. Bortezomib EH. Recent Results Cancer Res 2010; 184:173-87; PMID:20072838
3. Driscoll JJ, Woodle ES. Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol 2012; 49:277-83; PMID:22726552; http://dx.doi.org/ 10.1053/j.seminhematol.2012.04.002
4. Hayden MS, Ghosh S. Shared principles in NFkappaB signaling. Cell 2008; 132:344-62; PMID:18267068; http://dx.doi.org/10.1016/j.cell.2008.01.020
5. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004; 18(Suppl 11):14-21; PMID:15688598
6. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010; 51:1178-87; PMID:20497001; http://dx.doi.org/10.3109/10428194.2010.483303
7. Berkowitz A, Walker S. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clin J Oncol Nurs 2012; 16:86-9; PMID:22297012; http://dx.doi.org/10.1188/12.CJON.86-89
8. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82:51-77; PMID:21908200; http://dx.doi.org/10.1016/j.critrevonc.2011.04.012
9. Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, Jann S, Cavaletti G. Role of a pre-existing neuropathy on the course of bortezomibinduced peripheral neurotoxicity. J Peripher Nerv Syst 2008; 13:267-74; PMID:19192066; http://dx.doi.org/10.1111/j.1529-8027.2008.00192.x
10. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86:1-15; PMID:20942854; http://dx.doi.org/10.1111/j.1600-0609.2010.01542.x
11. Brix Finnerup N, Hein Sindrup S, Staehelin Jensen T. Management of painful neuropathies. Handb Clin Neurol 2013; 115:279-90; PMID:23931787; http://dx.doi.org/10.1016/B978-0-444-52902-2.00017-5
12. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518-25; PMID:19528374; http://dx.doi.org/10.1200/JCO.2008.18. 3087
13. Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012; 3:117-24; PMID:23556118; http://dx.doi.org/10. 1177/2040620711432020
14. Thompson JL. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann Pharmacother 2013; 47:56-62; PMID:23300152; http://dx.doi.org/10.1345/aph.1R561
15. Pautasso C, Bringhen S, Cerrato C, Magarotto V, Palumbo A. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2013; 9:1371-9; PMID:23834482; http://dx.doi.org/10.1517/17425255.2013.817556
16. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 14:7340-7; PMID:19010849; http://dx.doi.org/10. 1158/1078-0432.CCR-08-0642
17. Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 2013; 39:124-31; PMID:24035926; http://dx.doi.org/10.1016/j.neuro.2013.09.001
18. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010; 14:343-50; PMID:19695912; http://dx.doi.org/10.1016/j. ejpain.2009.07.001
19. Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, Bossi M, Marmiroli P, Cavaletti G. Neurophysiological and neuropathological characterization of new murine models of chemotherapyinduced chronic peripheral neuropathies. Exp Neurol 2010; 226:301-9; PMID:20832406; http://dx.doi.org/10. 1016/j.expneurol.2010.09.004
20. Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 2010; 223:599-608; PMID:20188093; http://dx.doi.org/10.1016/j.expneurol.2010.02.006
21. Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 2010; 70:5870-9; PMID:20587529; http://dx.doi.org/10.1158/0008-5472.CAN-09-4281
22. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46:479-94; PMID:20045310; http://dx.doi.org/10.1016/j.ejca.2009.12.008
23. Shin YK, Jang SY, Lee HK, Jung J, Suh DJ, Seo SY, Park HT. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy. Glia 2010; 58:1961-76; PMID:20830808; http://dx.doi.org/10.1002/glia.21065
24. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27-46; PMID:18346229; http://dx.doi.org/10.1111/j.1529-8027.2008. 00156.x
25. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7:940-9; PMID:18414063; http://dx.doi.org/10.4161/cc.7.7.5625
26. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204:317-25; PMID:17214983; http://dx.doi.org/10.1016/j.expneurol.2006.11.010
27. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8:407-19; PMID:16286248; http://dx.doi.org/ 10.1016/j.ccr.2005.10.013
28. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22:304-11; PMID:15199612; http://dx.doi.org/ 10.1081/CNV-120030218
29. Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010; 17:167-78; PMID:19609631; http://dx.doi.org/10.1007/ s12640-009-9086-1
30. Palanca A, Casafont I, Berciano MT, Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci 2013; PMID:24061536; http://dx.doi.org/10.1007/s00018-013-1474-2
31. rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011; 67:57-67; PMID:20306195; http://dx.doi.org/10.1007/s00280-010-1283-3
32. McConkey DJ, White M, Yan W. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 2012; 116:131-63; PMID:23088870
33. Steffen J, Seeger M, Koch A, Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell 2010; 40:147-58; PMID:20932482; http://dx.doi.org/10.1016/j.molcel.2010.09. 012
34. Contini A, Cappelletti G, Cartelli D, Fontana G, Gelmi ML. Molecular dynamics and tubulin polymerization kinetics study on 1,14-heterofused taxanes: evidence of stabilization of the tubulin head-to-tail dimer-dimer interaction. Mol Biosyst 2012; 8:3254-61; PMID:23073462; http://dx.doi.org/10.1039/c2mb25326g
35. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013; 37:231-9; PMID:23711742; http://dx.doi.org/10.1016/j.neuro.2013.05.008
36. Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol 2001; 28:191-8; PMID:11251225; http://dx.doi.org/10.1016/S0141-8130(00)00159-8
37. Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009; 8:1026-36; PMID:19383850; http://dx.doi.org/10.1158/1535-7163.MCT-08-0700
38. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-21; PMID:15169797; http://dx.doi.org/10.1200/JCO.2004.02.106
39. Maggioni D, Nicolini G, Chiorazzi A, Meregalli C, Cavaletti G, Tredici G. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. J Neurosci Res 2010; 88:3171-9; PMID:20722073; http://dx.doi.org/10.1002/jnr.22465
40. Scuteri A, Donzelli E, Ravasi M, Tredici G. Adult mesenchymal stem cells support cisplatin-treated dorsal root ganglion survival. Neurosci Lett 2008; 445:68-72; PMID:18771708; http://dx.doi.org/10.1016/j.neulet.2008.08.056
41. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 2005; 41:1460-6; PMID:15913989; http://dx.doi.org/10.1016/ j.ejca.2005.04.006
42. Zimmermann M. Ethical considerations in relation to pain in animal experimentation. Acta Physiol Scand Suppl 1986; 554:221-33; PMID:3469880
43. Marmiroli P, Rodriguez-Menendez V, Rigamonti L, Tonoli E, Rigolio R, Cavaletti G, Tredici G, Vercelli A. Neuropathological changes in the peripheral nervous system and spinal cord in a transgenic mouse model of Niemann-Pick disease type A. Clin Neuropathol 2009; 28:263-74; PMID:19642505
44. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992; 84:364-71; PMID:1441917; http://dx.doi.org/10.1007/BF00227662
45. Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank AJ, Tredici G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 2006; 26(2A):1065-70; PMID:16619507
46. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005; 2:357-62; PMID:15846363; http://dx.doi.org/10.1038/nmeth759